# BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

> **NCT02393898** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 76 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02393898
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-23
- **Primary completion:** 2019-06-14
- **Final completion:** 2019-06-14
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02393898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02393898, "BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02393898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*